Theranica Announces Landmark Coverage Milestone as Nerivio® Exceeds Half of the U.S. Insured Population
Theranica Announces Landmark Coverage Milestone as Nerivio® Exceeds Half of the U.S. Insured Population (PR Newswire FDA.)
Theranica is a digital therapeutics company developing FDA-cleared neuromodulation devices for migraine and other neurological conditions. Nerivio, its wearable non-invasive vagus nerve stimulation device, became the first neuromodulation product to reach more than half of the U.S. insured population.
Theranica Announces Landmark Coverage Milestone as Nerivio® Exceeds Half of the U.S. Insured Population (PR Newswire FDA.)